

# Management of patients with transvalvular right ventricular leads undergoing transcatheter tricuspid valve interventions: a scientific statement of the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions of the ESC endorsed by the Heart Rhythm Society, the Asian Pacific Heart Rhythm Society and the Canadian Heart Rhythm Society

Jean-Claude Deharo <sup>1,2\*</sup>, Julien Dreyfus <sup>3</sup>, Maria-Grazia Bongiorno <sup>4</sup>, Haran Burri <sup>5</sup>, Pascal Defaye <sup>6</sup>, Michael Glikson <sup>7</sup>, Nigel Lever<sup>8</sup>, (APHRS representative), Antonio Mangieri<sup>9</sup>, Blandine Mondésert <sup>10</sup>, (CHRS representative), Jens Cosedis Nielsen <sup>11,12</sup>, Maully Shah<sup>13</sup>, (HRS representative), Christoph Thomas Starck <sup>14</sup>, Archana Rao <sup>15</sup>, Christophe Leclercq <sup>16</sup>, and Fabien Praz <sup>17</sup>

**Reviewers:** Sergio Richter<sup>18</sup>, (Review Coordinator), Nicolas Amabile, MD, PhD<sup>19</sup>, Alexander Breitenstein<sup>20</sup>, Óscar Cano, MD, PhD<sup>21,22</sup>, Karol Čurila<sup>23</sup>, Jamie Manlucu<sup>24</sup>, Robert D. Schaller<sup>25</sup>, Hung-Fat Tse<sup>26</sup>, Christian Veltmann<sup>27</sup>, and Zachary Whinnett<sup>28</sup>

<sup>1</sup>Assistance Publique – Hôpitaux de Marseille, Centre Hospitalier Universitaire La Timone, Service de Cardiologie, 264 Rue Saint-Pierre, 13005 Marseille, France; <sup>2</sup>Aix Marseille Université, C2VN, 13005 Marseille, France, Bd Jean Moulin, 13005 Marseille, France; <sup>3</sup>Department of Cardiology, Centre Cardiologique du Nord, Saint-Denis, France; <sup>4</sup>Heart Rhythm Clinic, San Rossore Hospital, Pisa, Italy; <sup>5</sup>Cardiac Pacing Unit, Cardiology Department, University Hospital of Geneva, Geneva, Switzerland; <sup>6</sup>Cardiology Department, Université de Grenoble Alpes, INSERM, CHU Grenoble Alpes, LRB, 38000 Grenoble, France; <sup>7</sup>Jesselson Integrated Heart Center, Shaare Zedek Medical Center and Hebrew University Faculty of Medicine, Jerusalem, Israel; <sup>8</sup>Department of Cardiology, University of Auckland and Auckland City Hospital, Auckland, New Zealand; <sup>9</sup>Cardio Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; <sup>10</sup>Department of Cardiology, Montreal Heart Institute, Université de Montréal, Montreal, Canada; <sup>11</sup>Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark; <sup>12</sup>Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; <sup>13</sup>Division of Pediatric Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, USA; <sup>14</sup>Department of Cardiothoracic and Vascular Surgery, German Heart Center of Charité, Berlin, Germany; <sup>15</sup>Department of Cardiology, Liverpool Heart & Chest Hospital NHS Foundation Trust, Liverpool, UK; <sup>16</sup>Department of Cardiology, University of Rennes, CHU Rennes, ITSI-UMR1099, Rennes F-35000, France; <sup>17</sup>Bern University Hospital, University of Bern, Bern, Switzerland; <sup>18</sup>Department of Cardiology, Heart Center Dresden, University Hospital, Technische Universität Dresden, Dresden, Germany; <sup>19</sup>Department of Cardiology, Institut Cardiovasculaire Paris Sud, Massy, France; <sup>20</sup>Senior Consultant in Electrophysiology, Head of Devices and Lead Extraction, University Heart Center, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland; <sup>21</sup>Department of Cardiology, Hospital Universitario y Politécnico La Fe, Valencia, Spain; <sup>22</sup>Department of Cardiology, Centro de Investigaciones Biomédicas en RED en Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain; <sup>23</sup>Cardiocenter, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech

\* Corresponding author. Tel: +33491386575. E-mail address: jean-claude.deharo@ap-hm.fr

© The European Society of Cardiology 2025.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<https://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com)


Republic; <sup>24</sup>London Health Sciences Centre, Western University, London, UK; <sup>25</sup>Electrophysiology Section, Division of Cardiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA; <sup>26</sup>Cardiology Division, Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China; <sup>27</sup>Zentrum Bremen, Herzzentrum Bremen, Klinikum Links der Weser, Senator-Weßling-Str. 1, 28277 Bremen, Germany; and <sup>28</sup>National Heart and Lung Institute, Imperial College London, Imperial College NHS Trust, London, UK

Received 25 January 2025; accepted after revision 14 March 2025; online publish-ahead-of-print 31 March 2025

## Abstract

Up to one-third of patients referred for transcatheter tricuspid valve intervention (TTVI) have a transvalvular pacemaker (PPM) or implantable cardioverter-defibrillator (ICD) lead in place. Both the electrophysiology and interventional cardiology communities have been alerted to the complexity of decision-making in this situation due to potential interactions between the leads and the TTVI material, including the risk of jailing or damage to the leads. This document, commissioned by the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions of the ESC, reviews the scientific evidence to inform Heart Team discussions on the management of patients with a PPM or ICD who are scheduled for or have undergone TTVI.

## Graphical Abstract



## Keywords

Transcatheter tricuspid valve intervention • cardiac implantable electronic device lead • tricuspid regurgitation • lead jailing • lead extraction

## Table of contents

1. Introduction.....	3	2.3. Detection of lead-related tricuspid regurgitation.....	4
2. Interactions between transvalvular cardiac implantable electronic devices leads and the tricuspid valve.....	3	3. Transcatheter tricuspid valve interventions and potential lead issues.....	4
2.1. Mechanisms.....	3	4. Potential risks due to lead jailing and device-lead interaction after transcatheter tricuspid valve intervention.....	5
2.2. Role of type of lead, position, and pacing mode.....	3	5. Risks and benefits of transvenous lead extraction.....	8
		5.1. Risks of transvenous lead extraction.....	8



5.2. Risks of tricuspid valve damage due to lead extraction.....	9
5.3. Lead extraction to reduce tricuspid regurgitation or prevent jailing.....	9
6. Valve-sparing pacing and implantable cardioverter-defibrillator strategies.....	10
7. Lead management in cardiac implantable electronic devices patients with planned transcatheter tricuspid valve intervention.....	12
7.1. Assess TR aetiology and suitability for transcatheter tricuspid valve intervention.....	12
7.2. Assess cardiac implantable electronic devices function before the procedure.....	13
7.3. Evaluate the need for (urgent) temporary pacing during transcatheter tricuspid valve intervention.....	13
8. Management of a patient with a jailed lead.....	14
8.1. Organize multidisciplinary follow-up (inform patient and caregivers).....	14
8.2. Planning for cardiac implantable electronic devices follow-up.....	14
8.3. Management and treatment of device-related infection.....	15
8.4. Management of malfunctioning jailed leads and upgrade procedures.....	15
9. Conclusion.....	15
10. Summary position.....	15
Acknowledgements.....	16
Supplementary material.....	16
Funding.....	16
Data availability.....	16

## 1. Introduction

The use of cardiac implantable electronic devices (CIED) has increased exponentially over the past two decades. According to data from the European Society of Cardiology (ESC), more than 600 permanent pacemakers (PPM), 100 implantable cardioverter defibrillators (ICDs), and 75 cardiac resynchronization therapy (CRT) devices are implanted per million inhabitants every year.<sup>1,2</sup>

A growing body of evidence shows that patients with progressive tricuspid regurgitation (TR) have a poorer prognosis in various clinical scenarios, including left heart failure, multivalvular disease,<sup>3,4</sup> and after CIED lead implantation.<sup>5</sup> Approximately one-third of patients referred for treatment of severe secondary TR have a transvalvular CIED lead implanted, which, in the majority of cases, is not the direct cause of TR (CIED-associated) but may interact during transcatheter tricuspid valve intervention (TTVI). A small but significant subgroup, representing approximately 5–7% of patients with relevant TR, has suspected CIED-related TR and requires specific diagnosis and management.<sup>6,7</sup>

Both the electrophysiology and interventional cardiology communities have been alerted to the complexity of decision-making in practice when performing TTVI in patients with pacemaker or defibrillator lead(s) crossing the tricuspid valve (TV), due to potential interactions between the leads and TTVI material, including the risk of jailing or damaging the lead(s). At the same time, both communities are becoming increasingly aware of the potential role of CIED leads in the occurrence/progression of TR.

Given the novelty of TTVI techniques, the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC have mandated this Task Force to create a Scientific Statement document highlighting the current scientific evidence regarding the increasingly common clinical problem of TTVI in patients with transvalvular CIED leads.

The present document is intended to serve as a basis for multidisciplinary discussions between the different healthcare professionals involved in decision-making for the management of patients with CIED scheduled for or undergoing TTVI. It reviews the potential interactions between CIED leads, TV and TTVI materials focusing on the respective risks and benefits of lead jailing and elective lead extraction. Finally, it addresses the most common situations in clinical practice.

## 2. Interactions between transvalvular cardiac implantable electronic devices leads and the tricuspid valve


### 2.1. Mechanisms

CIED-related TR is attributed to implantation-related, pacing-related, and device-related mechanisms. The incidence of TR worsening (by 1 or more grades) following CIED implantation vary from 10 to 39%.<sup>8,9</sup> Mechanisms are multiple, including: (i) Perforation and laceration of the TV,<sup>10</sup> presumably occurring during direct introduction of the lead into the right ventricle (RV) rather than 'prolapsing' the lead; (ii) Entanglement of the valve or the chordae, particularly when using tined leads;<sup>11</sup> (iii) Impingement on a leaflet (most commonly the septal one);<sup>12</sup> and (iv) Chronic dyssynchronous RV pacing, left ventricular dysfunction, and possibly RV dilatation. New flail leaflet may rarely be observed after implantation. Entanglement and impingement may later translate into fibrous adhesions between the lead and the TV/subvalvular apparatus (*Figure 1* and *supplementary movies*), resulting in valve dysfunction.<sup>10,13</sup> In addition, following transvenous lead extraction (TLE), TR can be the consequence of leaflet avulsion or chordal rupture. Finally, the presence of a transvalvular lead may predispose to endocarditis, which in turn can worsen TR.<sup>14</sup>

Procedural factors that impact the probability of valve damage include lead tip configuration,<sup>15,16</sup> tined leads being more likely to become entangled or entrapped in the chordae tendinae, and valve crossing technique. Prolapsing may reduce the risk of perforation compared with 'direct crossing' because of less head on trauma to the TV leaflets and sub-valvular apparatus.<sup>17</sup> Technical factors include the number, thickness, stiffness, and course of the lead across the valve.

### 2.2. Role of type of lead, position, and pacing mode

Studies failed to show clear differences between PPM and ICD leads regarding TV dysfunction despite the higher weight and rigidity of ICD leads.<sup>18–20</sup> Single-chamber RV pacing has been associated with TR progression,<sup>14,21–23</sup> presumably due to changes in RV geometry,<sup>24</sup> a risk that may be mitigated by the use of His bundle pacing.<sup>25</sup> Although investigated in a small patient population, His bundle pacing might reduce TR,<sup>25</sup> which has not been observed with left bundle branch stimulation,<sup>26</sup> especially in the case of a basal lead position.<sup>27</sup> Even without direct interaction with the TV leaflets, leadless cardiac pacemaker (LCPM) implantation may not fully exclude the occurrence of TR, which may be related to mechanical interference with the subvalvular apparatus<sup>28</sup> or to the pacing mode itself, as shown in an observational study including 53 patients followed up to 12 months.<sup>29</sup> However, a smaller study ( $N = 23$ ) with shorter observation period failed to show significant changes in RV and TV structure, as well as their function 2 months after LCPM implantation operating in the VVIR mode.<sup>30</sup>



**Figure 1** Mechanisms of interaction between CIED lead and the tricuspid valve. (A) Example of leaflet perforation with the CIED lead piercing the septal leaflet (within the circle) and impairing its mobility. (B) Example of subvalvular apparatus damage during CIED lead positioning causing a flail septal leaflet (indicated by the arrow) due to chordal rupture and severe eccentric TR. (C) Example of impingement of the septal leaflet through a CIED lead (indicated by the arrow), limiting its systolic mobility and causing severe TR. A, anterior leaflet of the tricuspid valve; CIED, cardiac implantable electronic device; P, posterior leaflet of the tricuspid valve; RA, right atrium; RV, right ventricle; S, septal leaflet of the tricuspid valve; TR, tricuspid regurgitation.

### 2.3. Detection of lead-related tricuspid regurgitation

In CIED recipients, a pre-implant imaging assessment is recommended by the 2021 ESC guidelines on cardiac pacing and CRT<sup>31</sup> and it may detect pre-existing TR and help refine the pacing strategy according to TR grade. Although there is no prospective scientific evidence to support this statement, detailed echocardiographic assessment of TV function in the weeks following CIED implantation should be encouraged to diagnose acute damage or adverse interaction with the leaflets or subvalvular apparatus<sup>6</sup> and to identify new-onset severe TR that may benefit from early intervention. This applies in particular to patients with technical or clinical risk factor(s) contributing to TR development as summarized in Table 1. Appropriate decisions regarding potential treatment and/or subsequent follow-up may prevent the deterioration

**Table 1** Risk factors for the development of significant tricuspid regurgitation in cardiac implantable electronic device recipients

Technical factors: directly related to CIED lead(s)
Lead placement technique (prolapsing vs. direct crossing)
TV passage angle and leaflet interaction <sup>32</sup>
Multiple leads crossing the tricuspid valve <sup>33</sup>
Clinical factors associated with TR development: no direct relationship with current CIED lead(s)
High burden of RV pacing (>90%) <sup>32</sup>
Permanent AF <sup>34</sup>
Pre- and post-capillary pulmonary hypertension <sup>34</sup>
RV dilatation <sup>34</sup>
Previous cardiac surgery on left heart valves <sup>34</sup>
Previous transvenous lead extraction <sup>35</sup>

AF, atrial fibrillation; CIED, cardiac implantable electronic device; RV, right ventricle; TR, tricuspid regurgitation; TV, tricuspid valve.

of RV function and heart failure symptoms over the long term. Baseline and follow-up information are also crucial, since they will guide decisions in case a TTVI is considered.

## 3. Transcatheter tricuspid valve interventions and potential lead issues

While open-heart surgery is the first-line option in low-risk patients, the high mortality associated with TV surgery in higher risk patients, mostly due to patient comorbidities, old age, and late referral,<sup>36</sup> has encouraged the development of less invasive alternatives. Many TTVI procedures are still under investigation and numbers are expected to increase due to growing disease awareness and an ageing population.

Managing patients with CIED leads crossing the TV and causing CIED-related TR, or associated with TR, is challenging and warrants a thorough anatomic assessment before any TTVI. The magnitude of the problem is underscored by the consistently high number of patients with CIED reported in published studies, ranging from 11.8 to 36% (Table 2), even though CIED leads crossing the TV may limit the feasibility of transcatheter repair, particularly when the lead is interacting with the valve leaflets.<sup>46,49–52</sup> There are currently four commercially available transcatheter therapies for TR treatment. Potential interactions of these therapies with CIED leads are illustrated in Figures 2 and 3.

- (1) Transcatheter edge-to-edge repair (TEER): In analogy to its counterpart for the mitral valve, TEER aims to correct TR through leaflet approximation of the TV leaflets. Increasing evidence confirms the safety of tricuspid TEER and its efficacy to reduce TR using the two approved platforms, PASCAL<sup>44</sup> and TriClip<sup>51</sup> (Figure 2A). A recently published randomized controlled trial (TRILUMINATE) showed that tricuspid TEER using the TriClip system significantly improves quality of life and reduces heart failure hospitalizations at 2 years compared with medical therapy alone. However, no significant change in terms of mortality was observed.<sup>49</sup> Further research is certainly needed, as this study was designed to include patients with favourable anatomic criteria for tricuspid TEER who appear to have less advanced disease than those included in other commercial and study cohorts.<sup>53</sup> Approximately 20–30% of TEER procedures are performed

in the presence of a CIED lead crossing the TV.<sup>54</sup> There are two main scenarios:<sup>42</sup>

- (a) The lead is an innocent bystander without a causative role in TR. In this scenario, the lead is usually far from the grasping zone and does not hamper leaflet coaptation and motion. Interaction with the lead during valve intervention is usually minimal and does not add risk of device detachment or damage.
- (b) The lead has a causative role in TR. In this scenario, comprehensive imaging assessment is required to determine whether the lead is attached or fused to a valve leaflet. In case of intact lead mobility, TEER is likely to be successful and often implies displacing and/or fixing the lead into one of the commissures or between two clips (*Figure 3*).

Irrespective of the strategy adopted, a too close interaction of any TEER catheter and a CIED lead should be avoided, in particular when the grippers are in open position. Penetration of the exposed grasping teeth into the lead coating may result in a potentially irreversible entanglement in addition to possible damage to the lead. Valve recrossing can be challenging depending on the number and location of the implants and necessitate echocardiographic guiding.

- (2) Direct percutaneous annuloplasty: This procedure replicates the prosthetic surgical annuloplasty that addresses annular dilatation occurring in functional TR.<sup>43</sup> The Cardioband system has shown effective and durable TR reduction, along with substantial symptomatic improvement<sup>55</sup> (*Figure 2B*). Combination with TEER may be needed to optimize TR reduction in patients with advanced disease or those with a persisting pseudo-prolapse. However, annuloplasty can be challenging in the presence of a lead close to the postero-septal or antero-septal area due to problematic visualization during the implant and lead jailing is occasionally unavoidable. This needs to be evaluated carefully since, in addition to lead injury, fixed leaflet impingement leading to TR worsening is sometimes observed. Lead insertion or extraction (if not jailed) after transcatheter annuloplasty is doable.
- (3) Transcatheter tricuspid valve replacement (TTVR): This procedure aims to address TR through positioning of a transcatheter valve delivered from the femoral or jugular vein (*Figure 2C*). In the TRISCEND II randomized controlled study investigating the EVOQUE system, 38.2% of the patients treated with TTVR had a CIED lead at baseline.<sup>56</sup> A new pacemaker (mainly LCPM) was implanted in 27.8% of the pacemaker-naïve patients within 1 year (17.4% of the whole cohort) after the procedure. In the presence of a pre-existing lead across the TV, the CIED is jailed between the annulus tissue and the self-expanding bioprosthesis precluding the option of subsequent lead extraction.
- (4) Caval valve implantation (CAVI): Caval valve implantation represents a symptomatic treatment option for patients who cannot undergo valve repair or replacement. The goal of this therapy is to mitigate the consequences of TR backflow, improve renal congestion, and better control volume overload (*Figure 2D*). Beside positive effects on symptoms, reverse RV remodelling has been observed in a prospective observational study. Approximately 22% of patients who receive CAVI have a CIED. Although the presence of leads does usually not mitigate the effectiveness of CAVI, it creates extensive entrapment in the superior vena cava of all intracardiac leads and (atrial) lead dislocation has been described.<sup>57</sup> Moreover, the presence of a valve that covers the brachiocephalic vein confluence may limit repeat lead implantation.

## 4. Potential risks due to lead jailing and device-lead interaction after transcatheter tricuspid valve intervention

The survival of patients with pre-existing CIED systems continues to improve, and the prevalence of both lead-related and lead-associated secondary TR will continue to rise.<sup>5</sup> This implies that the number of

**Table 2** Summary of published studies on transcatheter tricuspid valve interventions in patients with CIED leads


Study reference	Patients (N)	Patients with transvenous leads (N)	System used for TTVI	TLE	Patients with jailed leads (N)	Lead complications	New Conduction disturbance	FU duration
FORMA <sup>37</sup>	19	3	FORMA	No	None	No issues reported	None reported	Mean 32 months (24–36)
T-TEER in CIED patients <sup>38</sup>	102	33	MitraClip	No	12/33 clips close to RV lead	Slight increase in thresholds (1 RA, 1 LV, 1 RV)	None reported	1 day (0–188 days)
GATE <sup>39</sup>	5	1	NaviGate system	No	1	No change in threshold (died day 28)	1 temporary PPM and no definitive one	3–6 months
CAVI (Sapien) <sup>40</sup>	25	9	Sapien Single caval (IVC), N = 19 Bicaval, N = 6	No	Unknown (BiCaval + PPM unknown)	No issue reported	None reported	316 ± 453 days

Continued

Table 2 Continued

Study reference	Patients (N)	Patients with transvenous leads (N)	System used for TTVI	TLE	Patients with jailed leads (N)	Lead complications	New Conduction disturbance	FU duration
VIVID Valve in valve registry <sup>41</sup>	329	128 with CIED 58 with transvenous leads 31 with leads crossing the TV	Sapien Melody Valve in previous surgical valve or repair	3 before	28	Dislodgement: 1 Impedance and threshold increase: 1 Fracture M7: 1	None reported	Median 15.1 months
TriValve <sup>42</sup>	470	121	MitraClip (87%) CAVI FORMA Cardioband NaviGate Pascal	No	Not reported	No dislodgement No dysfunction	None reported	Median 7 months (1.15–20.00)
TRI-REPAIR <sup>43</sup>	30	4	Cardioband	No	Not reported	No issue reported	Conduction system disturbance: 2	2 years
PASTE <sup>44</sup>	235	72	PASCAL	No	Not reported	No lead issue reported; half of the SLDA occurred in patients with leads	None reported	Median follow-up of 173 days
1-year FU with EVOQUE system (compassionate use) <sup>45</sup>	27	9	EVOQUE	No	9	No dislodgement No dysfunction	–2 new PPM < day 3 –1 new PPM day 31	379 days (197–468)
TRISCEND I <sup>46</sup>	176	57	EVOQUE	No	57	No information	15 patients (13.3% of CIED-naïve patients) required new pacemaker implantation	1 year
TRICENTO <sup>47</sup>	21	3 + 1 extracted before and implanted with a Micra	Bicaval stent	No (1 before)	3	No issue reported	None reported	1 year
TRILUMINATE single arm <sup>48</sup>	98	14	TriClip	No	Not reported	No issue reported	2 patients received a new pacemaker within 3 years	3 years
TRILUMINATE RCT <sup>49</sup>	175 (170 received the device)	28	TriClip	No	Not reported	No issue reported	Not precisely reported (5 new CIEDs at 1 year)	12 months





**Figure 2** Contemporary transcatheter treatment methods of tricuspid regurgitation and their interaction with CIED leads. (A) Transcatheter edge-to-edge repair; (B) Direct annuloplasty; (C) Transcatheter tricuspid valve replacement; (D) Heterotopic CAVI in both venae cavae.

jailed leads is also expected to increase in the near future. The incidence of lead jailing during TTVI varies from 0 to 33% (Table 2). Although major mechanical or electrical lead dysfunction has been rarely reported, the long-term risk has not been evaluated and is largely unknown. Importantly, no details regarding CIED, including pacing-dependency, lead type or defibrillation coils and indications for CIED therapy, are available in the majority of the studies (Table 2).


In a large dataset of 329 patients undergoing tricuspid valve-in-valve or valve-in-ring procedures,<sup>41</sup> a lead complication rate of 10.7% was observed over a median follow-up of 15.2 months in 28 patients who had jailed leads. Importantly, these patients had their lead jailed between two metallic structures (surgical valve or ring and the stent frame of the newly implanted transcatheter heart valve) and not between metal and tissue as it is the case for TTVI performed in native valves or CAVI. In the largest registry series of patients undergoing TEER, there were no reports of lead damage during short-term follow-up (median 6.2 months), although very limited information on lead type and function is available.<sup>58</sup> In a small number of patients treated with transcatheter TV annuloplasty, no adverse events related to jailed leads were reported.<sup>55</sup> At 1 year, no CIED-related complications were described in 9 patients with pre-existing CIED leads who underwent bicaval valve implantation.<sup>59</sup>

The risks associated with CIED lead jailing are summarized in Figure 4. The overall risk of lead damage in this context remains unclear and is potentially related to the lead composition, dwell time and location, as well as the properties of the valve deployed. Transvenous leads are exposed to considerable mechanical and biological stressors within the vascular space, and any tricuspid prostheses jailing them is expected to have additional impact on subsequent lead performance. Lead dislodgement or damage may necessitate revision or replacement, which increases the risk of venous occlusion, as well as infection. Extraction of jailed lead may not be feasible.<sup>60</sup> The reported rate of mid-term dysfunction is not negligible prompting careful patient and device evaluation before considering lead jailing. This includes patients with complete pacemaker dependency or prior use of ICD for treatment of arrhythmias, as well as those with previous CIED infection. In these situations, if doable, lead extraction may be preferred to avoid lead jailing (Figure 5).

Only limited short-term lead safety data exists on leads jailed by stents in both the innominate vein and superior vena cava.<sup>61,62</sup> Case reports for both scenarios have been published at this early stage. Some report lead failure at 2 weeks,<sup>63</sup> others freedom from failure at 1 year.<sup>59</sup>

Another major concern is the risk of infection with need of lead extraction. The risk of CIED infection increases with re-interventions on the device, from around 1% after the first CIED implantation, and approximately doubling with each additional re-intervention.<sup>64</sup> Other risk factors for CIED infection are listed in Table 3. Cardiac implantable electronic devices infections are associated with increased mortality.<sup>66</sup> The number of CIED-infections is expected to increase with the growing pool of CIED-patients and the presence of TTVI material interacting with an infected CIED to complicate treatment. The risk of endocarditis associated with TTVI is not known and existing literature is very limited. There is agreement that CIED infection is best treated with complete CIED system removal,<sup>67</sup> typically including TLE. One case report presented successful TLE of both a pacing and a defibrillator lead jailed around a surgical tricuspid bioprosthesis in a patient with CIED pocket infection.<sup>68</sup> However, both leads could be extracted without passing the TV with the extraction sheath. In another case of CIED pocket infection in a patient after TTVR, extraction of the jailed ICD lead was not attempted due to the risk of dislodging and embolizing the bioprosthesis.<sup>69</sup> We found no published reports on patients with indwelling RV pacing or defibrillator lead(s) who had received TEER and afterwards developed CIED infection with need for TLE.

Jailed leads often have long dwell-time and are adherent to the TV leaflets. Percutaneous extraction of jailed leads therefore carries a risk of TV laceration or damage and likely new TR in patients treated with TEER, as well as valve dislodgement after TTVR. There is no literature concerning the risk of TV endocarditis after TTVI in patients with CIED-infection. Case reports indicate that mitral valve endocarditis after transcatheter mitral valve repair has a deleterious prognosis, is best treated by surgery, whereas frequently the alternative of long-lasting antibiotics must be chosen.<sup>70,71</sup> Similarly, extensive valve surgery may not be appropriate in elderly patients undergoing TTVI who will need to be managed conservatively.



**Figure 3** Examples of interactions between tricuspid devices and CIED lead. (A–B) Implantation of 2 TriClips (\*antero-septal coaptation line; \*\*postero-septal coaptation line) with PM lead in-between (arrow); (C) Jailed PM lead after direct annuloplasty using the Edwards Cardioband system; (D–F) Interaction between the Lux valve and a jailed CIED RV lead as seen using echocardiography-fluoroscopy fusion imaging (D) and computed tomogram (E–F).


## 5. Risks and benefits of transvenous lead extraction

Lead extraction needs to be carefully evaluated during the planning of TTVI through a multidisciplinary discussion taking into account individual risks of transvenous lead extraction (TLE) and a thorough evaluation of the mechanism and the anatomic relationship between the lead and the valve.<sup>6,72</sup>

### 5.1. Risks of transvenous lead extraction

TLE has evolved during the last 20 years and updated consensus documents with well-defined indications, definitions and outcomes are available.<sup>73,74</sup> It represents the cornerstone of the management of infected and malfunctioning CIED leads.<sup>75–77</sup> European Heart Rhythm Association surveys<sup>78</sup> and the ELECTRa (European Lead Extraction

Controlled) Registry (N = 3510)<sup>79</sup> provided a snapshot of the clinical practices and physicians' attitudes towards TLE in Europe. Despite the development of different techniques<sup>80–85</sup> and approaches,<sup>86–88</sup> TLE rarely leads to major complications (1.7%) and death (0.5%).<sup>89–94</sup> Patient-related (age, sex, comorbidities, indications)<sup>95–100</sup> and lead-related factors (dwell time, lead and insulator type, design, fixation mechanisms, coil technologies,) may be associated with different risk profiles (Table 4).<sup>101–111</sup> The factors with the highest risk are, in decreasing order, female sex, the number of leads to be extracted, the presence of coagulopathy, limited operator or centre experience, and low body mass index. A relationship has been suggested between operator and centre volumes and outcomes.<sup>112,113</sup> Educational pathways<sup>73,114</sup> have been advocated in order to minimize TLE related complications. Procedure-related major complications including death were more frequent in women, in case of a dwell time >10 years and when powered sheaths or a femoral approach was used for TLE.



Several TLE risk stratification tools have been published so far but none is routinely used in clinical practice.<sup>115–120</sup> These scores show that the lead dwell time (>10 or 15 years for pacemaker leads and >5 or 10 years for defibrillator leads) and their number (increased risk for each lead beyond one) contribute most to the procedural risk. Machine learning may have an incremental value to predict adverse events, but has yet to be applied on large scale populations.<sup>119</sup>

Age has been reported as a factor increasing the risk of complication during TLE, but this factor alone should not be considered a strict exclusion criteria. Indeed, according to a meta-analysis, octogenarians who are the main candidates for TTVI do not seem to have significantly higher mortality and major complications during or after TLE (RR 1.40 and 1.43, respectively, both not statistically significant).<sup>121</sup> On the other hand, severe left ventricular dysfunction or advanced heart failure increase the risk of complications (by a factor of 2) and the risk of 30-day mortality (by a factor of 1.3–8.5).<sup>75</sup>

## 5.2. Risks of tricuspid valve damage due to lead extraction


TLE is associated with a significant increase in the severity of TR in 3.5–15% of the cases,<sup>35,122–128</sup> which is likely explained by adhesions between the leads and the TV apparatus.<sup>129</sup> This complication can occur irrespective of the type of the tools used for extraction (passive or mechanical sheath) and is usually due to a new flail leaflet.<sup>123</sup> The most important risk factors for worsening TR following TLE were

longer lead dwell time and multiple leads crossing the TV. The use of several tools in the same patient has also been suggested as a potential cause, but is probably linked to the age of the lead and the complexity of adhesions. The medium-term prognosis of patients exposed to traumatic TR was shown to be changed, with new right-sided heart failure symptoms in a study of 208 patients,<sup>123</sup> while it was not the case in another smaller study.<sup>126</sup> The risk of damaging the valvular/subvalvular tricuspid apparatus should be taken into consideration when planning TLE before TTVI. A traumatic lesion of the TV could compromise the effectiveness of subsequent TTVI or even render the patient unsuitable for any transcatheter treatment. It is therefore crucial to carefully reassess patients after TLE to confirm the feasibility of TTVI and the most adequate technique to use. As it is not possible to anticipate all technical difficulties, a TLE procedure may be interrupted if a risk of a serious TV damage is detected.

## 5.3. Lead extraction to reduce tricuspid regurgitation or prevent jailing

There is limited information on the use of TLE alone as a treatment of chronic lead-related TR. Polewczyk *et al.*<sup>130</sup> studied the effect of TLE in 119 patients with lead-related TR, which improved in only 35%. Results were similar in another series,<sup>131</sup> and are even worse when there is co-existing TV annulus dilatation. In this respect, it makes sense that early detection of lead-related TR could allow TLE to be considered before annulus dilatation and extensive fibrosis occur.





**Figure 5** A proposal to assist multidisciplinary discussion: red and orange flags for lead jailing—in these situations transvenous lead extraction requires careful multidisciplinary discussion before TTVI. (\* see Table 3). CIED, cardiac implantable electronic device; ICD, implantable cardiac defibrillator; PM, pacemaker; TTVI, Transcatheter tricuspid valve intervention; TV, tricuspid valve.

For the indication of TLE, the exact mechanism of valve dysfunction must be analysed by 3D TEE and potentially CT,<sup>132,133</sup> which also provide information regarding TLE access, in particular the presence of lead fibrosis and vein stenosis.<sup>132,134</sup> In the presence of acute TV dysfunction due to leaflet impingement after CIED implantation, timely TLE (within 6 months) seems appropriate in order to minimize the risk of complication and avoid leaflet scarring.

When a lead is anticipated to prevent effective repair with TEER, a multidisciplinary discussion should take place considering the risk and benefits of TLE to facilitate TEER. In cases of TTVR, TLE combined with valve sparing lead implantation, or rarely transvalvular implantation through the new valve, should be weighed against the potential risks associated with lead jailing. Given the uncertainties regarding long-term consequences of jailing, lead extraction should also be discussed before stent placement in the superior vena cava.<sup>75,135</sup>

## 6. Valve-sparing pacing and implantable cardioverter-defibrillator strategies

Valve-sparing alternative pacing strategies have been proposed to mitigate lead-related TR and minimize interaction with implanted tricuspid devices (Table 5).<sup>136</sup> Since many patients undergoing TTVI have chronic atrial fibrillation, atrial pacing plays a limited role. Options for long-term ventricular pacing include coronary sinus pacing, surgical epicardial lead placement, LCPM implantation. Coronary sinus pacing presents an appealing option as it avoids valve disturbances. However, challenges such

as lead instability, phrenic nerve capture, and high capture thresholds limit its widespread adoption.<sup>137</sup> For safety, particularly in pacemaker-dependent patients, it may be appropriate to implant two leads in the coronary sinus and use quadripolar lead(s) (see Figure 6). Epicardial lead placement also avoids damage to endocardial structures but necessitates surgical access to the pericardium, which might be difficult in patients indicated for TTVI. In addition, it exhibits higher lead failure rates and often poorer electrical parameters for pacing/sensing compared with conventional transvenous leads and is often not ideal in case of previous heart surgery. Commercially available LCPM systems have low procedural and post-operative complication rates and can also be applied after TTVR (Figure 6). Although unlikely, LCPM implantation does not necessarily exclude the apparition of TV dysfunction,<sup>29</sup> in particular when implanted in septal position near the tricuspid valve annulus.<sup>28</sup> In an observational study of 54 patients receiving a LCPM, Arps et al.<sup>138</sup> found no alteration in TV function before and after implantation. In a small randomized study, Garweg et al.<sup>139</sup> compared 27 patients implanted with a Micra™ LCPM (Medtronic Inc., Minneapolis, MN, USA) to 24 other patients implanted with a conventional VVIR pacemaker and found no significant difference in TR between the two systems. Similarly, in a series of 23 patients implanted with a Micra™ VR or a Nanostim™ LCPM (Abbott Medical, Chicago, IL, USA), Salaun and colleagues reported no interaction of the devices with TV or RV function or anatomy.<sup>30</sup> Implanting physicians should be aware of potential interactions between RV LCPM and the material used for TTVI and adapt their implantation technique. A recent small series of patients implanted with LCPM following transcatheter or surgical TV repair or replacement confirms the feasibility and safety of such an approach. It also provides some technical guidance using

**Table 3** Risk factors for cardiac implantable electronic device lead infection

**Risk factors for CIED lead infection ordered from highest to lowest reported risk in each section (adapted from Blomstrom Lundqvist et al, Europace 2020)<sup>65</sup>**

Patient-related factors

End stage renal disease  
History of CIED infection  
Fever prior to implant  
Corticosteroid use  
Renal failure  
Chronic obstructive pulmonary disease  
NYHA  $\geq 2$   
Skin disorders  
Malignancy  
Diabetes mellitus  
Heparin bridging  
Chronic heart failure  
Oral anticoagulants

Device-related factors

Abdominal pocket  
 $\geq 2$  leads  
Dual chamber device

CIED, cardiac implantable electronic device; NYHA, New York Heart Association.

**Table 4** Risk factors for severe transvenous lead extraction complication

**Risk factors for severe TLE complication (adapted from Deharo et al, Europace 2012<sup>73</sup> and Kusumoto et al. Heart Rhythm 2017<sup>75</sup>)**

Patient-related factors

Low body mass index ( $<25 \text{ kg/m}^2$ )  
Female sex  
Comorbidities, age, poor LV function, renal failure, coagulopathy, large vegetations  
Occluded or severely stenosed venous access  
Congenital heart disease with complex cardiac anatomy  
Prior cardiac surgery lowers the risk of complications

Technical factors

Number of leads present or extracted  
Passive fixation mechanism  
Lead body geometry (non-isodiametric)  
ICD lead  
Dwell time greater than 1 year  
Special/damaged/deficient leads  
Limited operator and centre experience

LV, left ventricle; TLE, transvenous lead extraction; ICD, implantable cardioverter defibrillator.

**Table 5** Alternative pacing and implantable cardioverter defibrillator strategy in case of percutaneous tricuspid valve intervention

Pacemaker alternatives	ICD alternatives
Ventricular pacing through coronary sinus	Subcutaneous-ICD (S-ICD <sup>TM</sup> )
Epicardial pacing: may allow for dual chamber pacing or CRT	Extra-Vascular-ICD (EV-ICD <sup>TM</sup> )
Leadless pacing (Micra <sup>TM</sup> or Aveir <sup>TM</sup> ): may allow for AV synchrony (Micra AV <sup>TM</sup> ) or dual chamber pacing (Aveir DR <sup>TM</sup> )	S-ICD + leadless RV device for ATP and pacing (Empower <sup>TM</sup> )
Left ventricular leadless pacing (WiSE-CRT <sup>TM</sup> )	Transvenous ICD with lead coil in the middle cardiac vein or azygos vein
Associated with Micra <sup>TM</sup> or Aveir <sup>TM</sup> : allows for CRT	and pace-sense lead in a coronary sinus branch (DF-1/IS-1 connection)


CRT, cardiac resynchronization therapy; AV, atrio-ventricular; ICD, implantable cardioverter defibrillator; S-ICD, subcutaneous implantable cardioverter defibrillator; RV, right ventricle; ATP, antitachycardia pacing.

fluoroscopic landmarks to implant the device at a site distant from the TV apparatus.<sup>140</sup> In case of the necessity of resynchronization, a total leadless CRT can be delivered with a combination of Micra<sup>TM</sup> or Aveir<sup>TM</sup> (Abbott Medical, Chicago, IL, USA) and WiSE-CRT<sup>TM</sup> (EBR Systems, Sunnyvale, CA, USA) systems.<sup>141</sup>

His bundle pacing is another option, enabling a more physiologic electromechanical activation of the ventricles. Studies have shown no alteration of TV function with even TR reduction in some cases.<sup>25</sup> However, interactions with the TV cannot be ruled out with this technique and implantation may be difficult in case of previous TTVI. Additionally, His bundle pacing leads can be impacted by mechanical disturbances to the conduction system potentially caused by TTVR and will have to be monitored intra- and post-operatively. TV crossing to achieve left bundle branch area (LBBA) pacing (rather than conventional pacing) is an acceptable option in patients with high pacing need or those with reduced LVEF requiring resynchronization. Careful implantation (possibly under echocardiographic guidance) with assessment of valve function may help to overcome the challenges associated with this technique after TTVI.<sup>142</sup> In the future, LCPM allowing for LBBA pacing may become available. A very limited experience has been reported with the WiSE CRT system, which was not entirely leadless.<sup>143</sup>

If an ICD is necessary, a subcutaneous (S-ICD) or extra-vascular ICD (EV-ICD) are good options. The S-ICD can also be associated with the Empower<sup>TM</sup> Leadless pacemaker (Boston Scientific, St. Paul, MN, USA), designed to be paired with the S-ICD to provide pacing or ATP therapies at the time they are needed.<sup>144</sup> However, this system is currently not commercially available. Transvenous ICD lead placement alternatives exist, including positioning of the defibrillation coil in the middle cardiac vein of the coronary sinus or in the azygos vein, and a coronary sinus lead for sensing and pacing in a coronary sinus branch.

Ideally, the options of valve-sparing pacing and ICD therapy should be discussed in CIED candidates with relevant TR who may benefit from TTVI in the future. In these patients, the Heart Team discussion will help selecting the best pacing strategy to avoid leads crossing the TV (i.e. ventricular pacing with a leadless pacemaker or with lead(s) in the coronary sinus branches, subcutaneous, or extravascular ICD therapy).



It is reasonable to schedule pacing system interventions such as generator replacement, lead revision, or upgrade procedures prior to the planned TTVI to reduce the risk of infection.

## 7. Lead management in cardiac implantable electronic devices patients with planned transcatheter tricuspid valve intervention

All CIED patients with transvalvular leads who are planned for TTVI should undergo evaluation by a Heart Team<sup>6</sup> consisting of a cardiologist with dedicated TTVI expertise, a cardiac surgeon, a lead extraction specialist and a cardiac imaging specialist (Figure 7). The goal of the discussion is to answer the following questions:

- (1) What is the aetiology of the valvular pathology? Is it lead-related?
- (2) What is the risk associated with lead jailing depending on lead characteristics and use? Does the planned TTVI require prior TLE to facilitate the procedure and/or avoid lead jailing and what are the risks of such a TLE?

- (3) Is there a need for urgent temporary pacing during the procedure?
- (4) What are the options for valve-sparing pacing and ICD therapy?


Since TLE may be associated with damage to the leaflets or the subvalvular apparatus of the TV, as well as serious disabling or life-threatening complications, multidisciplinary evaluation has to integrate a thorough risk-benefit-analysis taking into account life-expectancy, comorbidities and valvular pathology of the individual patient.

In summary, the Heart Team should carefully weigh the risks and benefits of TLE. Examples of scenarios favouring TLE include patients with leads implanted for less than 10 years and those in whom advanced imaging has clearly demonstrated a lead-related TR mechanism.

### 7.1. Assess TR aetiology and suitability for transcatheter tricuspid valve intervention

Assessment of the mechanism of TR is essential in all patients considered for TTVI. This should be done using transthoracic and transoesophageal echocardiography in 2D and 3D modes, and CT if necessary.

A recent classification proposes a distinct aetiology group for patients with CIED-related TR, in addition to the traditional functional/secondary and organic/primary TR categories.<sup>54,145</sup> However, determining whether TR is related to a CIED lead can be challenging. Advanced imaging techniques, such as 3D echocardiography and



**Figure 7** Example of valve-sparing implantation techniques after transcatheter tricuspid valve interventions. (A) Implantation of a LCPM after TTVR with delivery tool crossing the transcatheter transjugular LUX valve system (RAO). (B) Definitive position of the LCPM in the same case (not shown in this LAO projection, the LCPM is implanted away from the LUX valve system). (C) A pacing lead implanted in a coronary sinus branch after TEER. (D) Two pacing leads implanted in two distinct coronary sinus branches (PPM-dependent patient) after TTVR with the LUX valve system. LAO, left anterior oblique view; LCPM, leadless cardiac pacemaker; RAO, right anterior oblique view; TEER, transcatheter edge-to-edge repair; TTVR, transcatheter tricuspid valve replacement.

multiplanar reconstructions, help to assess lead position, trajectory and interactions with anatomical structures in real time (Figure 1 and supplementary movies).<sup>146,147</sup> In advanced stages, differentiation between lead-related and lead-associated TR may be difficult due to RV remodelling. Cardiac CT, with its higher spatial resolution, can help diagnosing lead-leaflet interaction, measuring the annulus, assessing adjacent structures (e.g. right coronary artery) and anticipating the need for lead jailing.<sup>148</sup> Although less relevant for TEER,<sup>149</sup> it is mandatory for the evaluation of valve replacement and annuloplasty.

In addition, it is critical to report the number and exact location of CIED leads, as this may influence the treatment strategy.

## 7.2. Assess cardiac implantable electronic devices function before the procedure

In a patient with a pacemaker or ICD lead, the main risks during TTVR are damaging the lead(s) mainly the ventricular one passing through the TV or dislodgment of the lead(s) related to the catheter manipulation. Damage of the leads may also occur late after the intervention.

Before any TTVI, complete details of the implanted system must be available (Figure 7). For ICD, the type and frequency of therapy use should be recorded. Figure 5 highlights the two main periprocedural concerns: pacemaker dependency and the presence of an ICD with prior therapy. In case of full pacemaker dependency, an asynchronous mode can be programmed just before the intervention to avoid sensing

interferences. The need for temporary pacing should be anticipated (see specific section).


Reassessment of the electrical parameters has to be performed immediately after the procedure, and compared with the pre-operative measurements to detect potential lead(s) dysfunction.

Ideally, as the damage of the leads may occur late after the intervention (even if the probability is largely unknown), a remote monitoring follow-up is the preferred option to detect late lead dysfunction.

## 7.3. Evaluate the need for (urgent) temporary pacing during transcatheter tricuspid valve intervention

Based on device interrogation, in particular if the patient is pacing dependent (i.e. has inadequate or even absent intrinsic rhythm and therefore can suffer significant symptoms or cardiac arrest after cessation of pacing) the risks of lead dislodgement or damage during TTVI should be carefully anticipated.<sup>150</sup> In general, it seems reasonable to ensure the stability of electrical parameters after CIED implantation whenever possible, if TTVI is planned.

After TTVI, new conduction disturbances have been reported (Table 2) and are much more frequent after valve replacement.<sup>45</sup> Therefore, risk anticipation and preventive measures need to be integrated into pre-procedural planning.



In patients considered high risk, i.e. those who are pacemaker-dependent or may become pacemaker-dependent, the interventional team should be prepared to install preventive or bailout temporary pacing strategies that preferably do not cross the TV. This includes preemptive coronary sinus lead placement, as well as emergency pacing options like LV or RV wire pacing.<sup>6</sup> RV temporary pacing leads should be avoided during TTVI, since lead positioning and retrieval can be challenging. In case of temporary pacing failure, transient patch pacing may be required, but can be generally avoided with adequate planning.

## 8. Management of a patient with a jailed lead

### 8.1. Organize multidisciplinary follow-up (inform patient and caregivers)

All CIED patients with jailed lead(s) after TTVI should be evaluated by an electrophysiologist with specific cardiac device expertise, in addition to the interventional cardiologist with TTVI expertise. The multidisciplinary follow-up should focus on:

- (1) The TTVI material jailing the lead(s), including all details of potential interactions between this material and the implanted lead(s)
- (2) The indication for CIED implantation and the current underlying cardiac rhythm (i.e. pacemaker dependence or not) and device use (percentage of pacing in each cavity and previous arrhythmia and therapy delivered by the device in the case of an ICD).

The team in charge of the follow-up should ensure that the patient and his caregivers are properly informed about potential lead failure<sup>75</sup> and/or device infection.<sup>65</sup> Due to the risks associated with CIED infection, all CIED procedures should be performed using all available preventive measures.<sup>67</sup> Appropriate follow-up of the CIED and TTVI devices should be planned (see following section) with particular attention to signs of lead failure and interactions between the TTVI material and lead(s) (Figure 8).

### 8.2. Planning for cardiac implantable electronic devices follow-up

An immediate peri-procedural interrogation of the CIED is indicated to detect damage to hardware (Table 6). The 2021 ESC guidelines on cardiac pacing and CRT recommend using remote monitoring for



**Table 6** CIED follow-up in patients with TTVI and jailed leads

CIED interrogation	Pacing threshold
	Lead impedance
	Sensing value
	Pacing/sensing percentages
	ICD therapies
Fluoroscopy	Oversensing issues
	• Risk of asystole due to pacing inhibition
	• Risk of inappropriate ICD therapy
Echocardiography	In case CIED interrogation shows abnormalities
	Function of the repaired or replaced TV

CIED, cardiac implantable electronic device; ICD, implantable cardioverter defibrillator; TV, tricuspid valve.

earlier detection of technical issues in pacemaker and CRT patients, particularly those at increased risk.<sup>31</sup> The 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death recommend remote monitoring also for patients with ICD to reduce inappropriate ICD-therapy.<sup>151</sup> Follow-up of a patient with jailed lead(s) is comparable to a patient with a lead under alert/recall.<sup>152</sup> In cases where acoustic or vibration-based device alerts are available, they should be activated, and patients instructed accordingly. If alerts and remote follow-up are not available, frequent (every 3 months) outpatient visits are required (Figure 8). Close follow-up is especially relevant in cases of pacing or ICD dependency.

Regular echocardiographic exams are required to assess the function of the repaired or replaced TV and whether the jailed lead(s) may affect long-term treatment efficacy (Table 6).

8.3. Management and treatment of device-related infection

There is currently insufficient data to guide the management of patients with infectious complications after TTVI. As shown in Figure 8, in this highly concerning situation therapeutic decisions should be taken in a multidisciplinary way and rely on patient status and preferences, as well as the type of infection, which may be limited to the pocket or a bloodstream infection with lead or valve endocarditis.

As a first step, the extent of a desired treatment should be defined according to the patient's preference, especially since the population qualifying for TTVI is elderly and at high surgical risk with multiple comorbidities (Figure 8).

With regard to the management of jailed leads in patients with transcatheter TV devices, when TLE must be performed due to infection, two different scenarios need to be differentiated: infection without TV involvement vs. infection with TV involvement (i.e. TV endocarditis).

In patients without signs of involvement of the TV device, an approach with explantation of all parts of the system including transvenous extraction of all leads including jailed leads and preservation of the TV device may be attempted, although challenging.<sup>68</sup> In patients with infection involving the TV, a curative treatment concept consists of surgical explant of the TV device and surgical TV repair or replacement, as well as CIED explant including extraction of all leads.<sup>153</sup>

In both scenarios, adequate antibiotic therapy is started and maintained, ideally and if possible guided by infectious disease specialists. If

CIED reimplantation is needed, valve-sparing reimplantation techniques should be preferred (Figure 8).

In patients deemed too frail or unwilling to undergo a TLE attempt (likely a high proportion of the patients undergoing TTVI), long-term suppressive antibiotic treatment can be offered, considering the less favourable infectious prognosis associated with such a strategy.<sup>153–155</sup> Local ultra-high dose antibiotic administration has been proposed, but the Task Force considers it investigational at this time.<sup>156</sup>

8.4. Management of malfunctioning jailed leads and upgrade procedures

In case of lead malfunction, an electrophysiologist with specific device expertise should take the most appropriate decision, depending on patient clinical status and the type of lead malfunction, most likely to replace the lead. However, removal of jailed leads is generally not an option and the reimplantation or upgrade (i.e. from conventional pacing to CRT or to ICD therapy) should favour a valve-sparing option (see specific section). For example, for CRT, a coronary sinus lead is preferred to an LBBA pacing lead. For defibrillation, extracardiac or coronary sinus/azygous vein options are preferred over endovascular RV defibrillation lead implantation. In the event of vein occlusion and the need for a new lead, venoplasty or implantation of a contralateral lead is mandatory, as TLE is not an option to achieve vein patency.

9. Conclusion

This scientific statement document emphasizes the importance of the Heart Team management and decision-making of TTVI candidates for the treatment of symptomatic severe TR and a lead crossing the TV. Specific scientific data on lead dysfunction, infectious risk and durability of outcomes after TTVI are still scarce and could be improved through dedicated registries. However, “red flags” that may indicate a higher risk of adverse events following lead jailing need to be considered in pre-interventional discussions and alternatives evaluated. TLE before TTVI remains a viable option, integrating the higher risk in this fragile, often elderly patient population. In situations where leads are jailed, frequent monitoring is desirable, particularly in patients who are pacemaker-dependent or who have an ICD indication for secondary prevention.

10. Summary position

*Scientific evidence concerning TTVI in patients with CIED leads is scarce and comes from observational studies or first-in-human reports.*

**CIED-related tricuspid regurgitation:** Interactions between transvalvular CIED leads and the TV may result into CIED-related TR and predisposing factors have been identified. Physician awareness around this complication and echocardiographic follow-up of patients at risk are needed to allow for early detection and management of CIED-related TR.

**Potential CIED lead issues with transcatheter tricuspid valve interventions:** between 11.8 and 36% of candidates for TTVI have transvenous CIED leads. Attitudes towards lead management in TTVI are heterogeneous due to the lack of scientific evidence. So far, experience with lead jailing is limited but lead failure or dislodgement have been

Continued

## Continued

reported and are a matter of concern. High risk situations for lead jailing and the general patient clinical condition should be taken into consideration before final decision.

Due to the novelty of the technique, there are very few reports of CIED-related infections in patients with jailed leads and management is uncertain in this high-risk population. The consensual management of CIED infections applies to patients who have had TTVI but the approach must be adapted on a case-by-case basis, particularly in the event of jailed leads.

**Transvenous lead extraction to prepare for transcatheter tricuspid valve intervention:** contemporary data show that complications of transvenous lead extraction are rare but can occur. Peri-procedural mortality is reported at 0.5% and major complications at 1.7%. TR reduction following TLE is unlikely and the TV can be damaged by TLE. Risk factors for complicated TLE need to be taken into account for individualized Heart Team decision-making. Safe and feasible valve-sparing PPM/ICD techniques have been extensively studied out of TTVI. Small series emphasize their role in patients with TTVI.

**Heart Team discussion and patient engagement:** due to the above-mentioned lack of strong scientific evidence in this area, we believe that a Heart Team case-by-case discussion is essential for each patient with a CIED who is scheduled for TTVI. Follow-up of a patient with jailed lead(s) after TTVI needs particular care and dedicated expertise to assess both TTVI result and lead integrity, as well as to manage complications. Due to the novelty and lack of knowledge, CIED patients who are candidates for TTVI should be informed about the benefits and risks of each approach.

**Need for increased evidence:** prospective systematic collection of CIED data in patients included in TTVI studies is encouraged. Reporting of longer-term systematic CIED follow-up data is desirable.

## Acknowledgements

The authors thank the EHRA Scientific Document Committee: Prof. Katja Zeppenfeld, Prof. Jens Cosedis Nielsen, Dr Luigi di Biase, Prof. Isabel Deisenhofer, Prof. Kristina Hermann Haugaa, Dr. Daniel Keene, Prof. Christian Meyer, Prof. Petr Peichl, Prof. Silvia Priori, Dr. Alireza Sepehri Shamloo, Prof. Markus Stühlinger, Prof. Jacob Tfelt Hansen, and Prof. Arthur Wilde.

## Supplementary material

Supplementary material is available at *Europace* online.

## Funding

None declared.

**Conflict of interest:** none declared.

## Data availability

No new data were generated or analysed in support of this research.

## References

1. <https://eatlas.escardio.org/Atlas/ESC-Atlas-of-Cardiology>.
2. Defaye P, Biffi M, El-Chami M, Boveda S, Glikson M, Piccini J et al. Cardiac pacing and lead devices management: 25 years of research at EP Europace journal. *Europace* 2023; **25**:eua202.
3. Tribouilloy C, Bohbot Y, Kubala M, Ruschitzka F, Popescu B, Wendler O et al. Characteristics, management, and outcomes of patients with multiple native valvular heart disease: a substudy of the EURObservational Research Programme Valvular Heart Disease II Survey. *Eur Heart J* 2022; **43**:2756–66.
4. d'Arcy JL, Coffey S, Loudon MA, Kennedy A, Pearson-Stuttard J, Birks J et al. Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: the OxVALVE Population Cohort Study. *Eur Heart J* 2016; **37**:3515–22.
5. Offen S, Strange G, Playford D, Celermajor DS, Stewart S. Prevalence and prognostic impact of tricuspid regurgitation in patients with cardiac implantable electronic devices: from the national echocardiography database of Australia. *Intern J Cardiol* 2023; **370**:338–44.
6. Andreas M, Burri H, Praz F, Soliman O, Badano L, Barreiro M et al. Tricuspid valve disease and cardiac implantable electronic devices. *Eur Heart J* 2024; **45**:346–65.
7. Van De Heyning CM, Elbarasi E, Masiero S, Brambatti M, Ghazal S, Al-Maashani S et al. Prospective study of tricuspid regurgitation associated with permanent leads after cardiac rhythm device implantation. *Can J Cardiol* 2019; **35**:389–95.
8. Paniagua D, Aldrich HR, Lieberman EH, Lamas GA, Agatston AS. Increased prevalence of significant tricuspid regurgitation in patients with transvenous pacemakers leads. *Am J Cardiol* 1998; **82**:1130–2.
9. Barclay JL, Cross SJ, Leslie SJ. Entanglement of passive fix ventricular lead in tricuspid valve. *Pacing Clin Electrophysiol* 2008; **31**:138.
10. Novak M, Dvorak P, Kamaryt P, Slana B, Lipoldova J. Autopsy and clinical context in deceased patients with implanted pacemakers and defibrillators: intracardiac findings near their leads and electrodes. *Europace* 2009; **11**:1510–6.
11. Schilling RJ. Pacing lead entanglement in the tricuspid valve apparatus during implantation. *Europace* 1999; **1**:201.
12. Rothschild DP, Goldstein JA, Kerner N, Abbas AE, Patel M, Wong WS. Pacemaker-induced tricuspid regurgitation is uncommon immediately post-implantation. *J Interv Card Electrophysiol* 2017; **49**:281–7.
13. Lin G, Nishimura RA, Connolly HM, Dearani JA, Sundt TM, Hayes DL. Severe symptomatic tricuspid valve regurgitation due to permanent pacemaker or implantable cardioverter-defibrillator leads. *J Am Coll Cardiol* 2005; **45**:1672–5.
14. Chang JD, Manning VJ, Ebrille E, Zimetbaum PJ. Tricuspid valve dysfunction following pacemaker or cardioverter-defibrillator implantation. *J Am Coll Cardiol* 2017; **69**:2331–41.
15. Res JC, De Cock CC, Van Rossum AC, Schreuder J. Entrapment of tined leads. *Pacing Clin Electrophysiol* 1989; **12**:1583–5.
16. Fürstberg S, Bluhm G, Olin C. Entrapment of an atrial tined pacemaker electrode in the tricuspid valve—a case report. *Pacing Clin Electrophysiol* 1984; **7**:760–2.
17. Rajappan K. Permanent pacemaker implantation technique: part II. *Heart* 2009; **95**:334–42.
18. Schleifer JW, Pislaru SV, Lin G, Powell BD, Espinosa R, Koestler C et al. Effect of ventricular pacing lead position on tricuspid regurgitation: a randomized prospective trial. *Heart Rhythm* 2018; **15**:1009–16.
19. Tatum R, Maynes EJ, Wood CT, Deb AK, Austin MA, O'Malley TJ et al. Tricuspid regurgitation associated with implantable electrical device insertion: a systematic review and meta-analysis. *Pacing Clin Electrophysiol* 2021; **44**:1297–302.
20. Anvardeen K, Rao R, Hazra S, Hay K, Dai H, Stoyanov N et al. Lead-specific features predisposing to the development of tricuspid regurgitation after endocardial lead implantation. *CJC Open* 2019; **1**:316–23.
21. Al-Bawardy R, Krishnaswamy A, Bhargava M, Dunn J, Wazni O, Tuzcu EM et al. Tricuspid regurgitation in patients with pacemakers and implantable cardiac defibrillators: a comprehensive review. *Clin Cardiol* 2013; **36**:249–54.
22. Lee RC, Friedman SE, Kono AT, Greenberg ML, Palac RT. Tricuspid regurgitation following implantation of endocardial leads: incidence and predictors. *Pacing Clin Electrophysiol* 2015; **38**:1267–74.
23. Fanari Z, Hammami S, Hammami MB, Hammami S, Shuraih M. The effects of right ventricular apical pacing with transvenous pacemaker and implantable cardioverter defibrillator on mitral and tricuspid regurgitation. *J Electrocardiol* 2015; **48**:791–7.
24. Vaturi M, Kusnec J, Shapira Y, Nevzorov R, Yedidya I, Weisenberg D et al. Right ventricular pacing increases tricuspid regurgitation grade regardless of the mechanical interference to the valve by the electrode. *Eur J Echocardiogr* 2010; **11**:550–3.
25. Zaidi SMJ, Sohail H, Satti DI, Sami A, Anwar M, Malik J et al. Tricuspid regurgitation in his bundle pacing: a systematic review. *Ann Noninvasive Electrocardiol* 2022; **27**:e12986.
26. Li X, Zhu H, Fan X, Wang Q, Wang Z, Li H et al. Tricuspid regurgitation outcomes in left bundle branch area pacing and comparison with right ventricular septal pacing. *Heart Rhythm* 2022; **19**:1202–3.
27. Bednarek A, Kielbasa G, Moskal P, Ostrowska A, Bednarski A, Sondej T et al. Left bundle branch area pacing improves right ventricular function and synchrony. *Heart Rhythm* 2024; **21**:2234–41.
28. Hai JJ, Mao Y, Zhen Z, Fang J, Wong CK, Siu CW et al. Close proximity of leadless pacemaker to tricuspid annulus predicts worse tricuspid regurgitation following septal implantation. *Circ Arrhythm Electrophysiol* 2021; **14**:e009530.
29. Beurskens NEG, Tjong FVY, de Bruin-Bon RHA, Dasselara KJ, Kuijt WJ, Wilde AAM et al. Impact of leadless pacemaker therapy on cardiac and atrioventricular valve



- function through 12 months of follow-up. *Circ Arrhythm Electrophysiol* 2019;**12**:e007124.
30. Salaun E, Tovmassian L, Simonnet B, Giorgi R, Franceschi F, Koutbi-Franceschi L et al. Right ventricular and tricuspid valve function in patients chronically implanted with leadless pacemakers. *Europace* 2018;**20**:823–8.
  31. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM et al. 2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy. *Eur Heart J* 2021;**42**:3427–520.
  32. Yu YJ, Chen Y, Lau CP, Liu YX, Wu MZ, Chen YY et al. Nonapical right ventricular pacing is associated with less tricuspid valve interference and long-term progress of tricuspid regurgitation. *J Am Soc Echocardiogr* 2020;**33**:1375–83.
  33. De Cock CC, Vinkers M, Van Campe LC, Verhorst PM, Visser GA. Long-term outcome of patients with multiple ( $\geq 3$ ) noninfected transvenous leads: a clinical and echocardiographic study. *Pacing Clin Electrophysiol* 2000;**23**:423–6.
  34. Wang TKM, Akuz K, Mentias A, Kirinich J, Duran Crane A, Xu S et al. Contemporary etiologies, outcomes, and novel risk score for isolated tricuspid regurgitation. *JACC Cardiovasc Imaging* 2022;**15**:731–44.
  35. Park S-J, Gentry JL, Varma N, Wazni O, Tarakji KG, Mehta A et al. Transvenous extraction of pacemaker and defibrillator leads and the risk of tricuspid valve regurgitation. *JACC Clin Electrophysiol* 2018;**4**:1421–8.
  36. Dreyfus J, Audureau E, Bohbot Y, Coisne A, Lavie-Badie Y, Bouchery M et al. TRI-SCORE: a new risk score for in-hospital mortality prediction after isolated tricuspid valve surgery. *Eur Heart J* 2022;**43**:654–62.
  37. Asmarats L, Perlman G, Praz F, Hensey M, Chrissoheris MP, Philippon F et al. Long-term outcomes of the FORMA transcatheter tricuspid valve repair system for the treatment of severe tricuspid regurgitation: insights from the first-in-human experience. *JACC Cardiovasc Interv* 2019;**12**:1438–47.
  38. Lurz J, Rommel KP, Unterhuber M, Besler C, Noack T, Borger M et al. Safety and efficacy of transcatheter edge-to-edge repair of the tricuspid valve in patients with cardiac implantable electronic device leads. *JACC Cardiovasc Interv* 2019;**12**:2114–6.
  39. Hahn RT, George I, Kodali SK, Nazif T, Khalique OK, Akkoc D et al. Early single-site experience with transcatheter tricuspid valve replacement. *JACC Cardiovasc Imaging* 2019;**12**:416–29.
  40. Lauten A, Figulla HR, Unbehau A, Fam N, Schofer J, Doenst T et al. Interventional treatment of severe tricuspid regurgitation: early clinical experience in a multicenter, observational, first-in-man study. *Circ Cardiovasc Interv* 2018;**11**:e006061.
  41. Anderson JH, McElhinney DB, Aboulhosn J, Zhang Y, Ribichini F, Eicken A et al. Management and outcomes of transvenous pacing leads in patients undergoing transcatheter tricuspid valve replacement. *JACC Cardiovasc Interv* 2020;**13**:2012–20.
  42. Taramasso M, Gavazzoni M, Pozzoli A, Alessandrini H, Latib A, Attinger-Toller A et al. Outcomes of TTVI in patients with pacemaker or defibrillator leads: data from the TriValve registry. *JACC Cardiovasc Interv* 2020;**13**:554–64.
  43. Nickenig G, Weber M, Schuler R, Hausleiter J, Nabauer M, von Bardeleben RS et al. 6-Month outcomes of tricuspid valve reconstruction for patients with severe tricuspid regurgitation. *J Am Coll Cardiol* 2019;**73**:1905–15.
  44. Wild MG, Löw K, Rosch S, Gerçek M, Higuchi S, Massberg S et al. Multicenter experience with the transcatheter leaflet repair system for symptomatic tricuspid regurgitation. *JACC Cardiovasc Interv* 2022;**15**:1352–63.
  45. Webb JG, Chuang AM, Meier D, von Bardeleben RS, Kodali SK, Smith RL et al. Transcatheter tricuspid valve replacement with the EVOQUE system: 1-year outcomes of a multicenter, first-in-human experience. *JACC Cardiovasc Interv* 2022;**15**:481–91.
  46. Kodali S, Hahn RT, Makkar R, Makar M, Davidson CJ, Puthumana JJ et al. Transfemoral tricuspid valve replacement and one-year outcomes: the TRISCEND study. *Eur Heart J* 2023;**44**:4862–73.
  47. Wild MG, Lubos E, Cruz-Gonzalez I, Amat-Santos I, Ancona M, Andreas M et al. Early clinical experience with the TRICENTO bicaval valved stent for treatment of symptomatic severe tricuspid regurgitation: a multicenter registry. *Circ Cardiovasc Interv* 2022;**15**:e011302.
  48. Nickenig G, Lurz P, Sorajja P, von Bardeleben RS, Sitges M, Tang GHL et al. Percutaneous edge-to-edge repair for tricuspid regurgitation: 3-year outcomes from the TRILUMINATE study. *JACC Cardiovasc Interv* 2024;**17**:2113–22.
  49. Sorajja P, Whisenant B, Hamid N, Naik H, Makkar R, Tadros P et al. Transcatheter repair for patients with tricuspid regurgitation. *N Engl J Med* 2023;**388**:1833–42.
  50. Taramasso M, Benfari G, van der Bijl P, Alessandrini H, Attinger-Toller A, Biasco L et al. Transcatheter versus medical treatment of patients with symptomatic severe tricuspid regurgitation. *J Am Coll Cardiol* 2019;**74**:2998–3008.
  51. Lurz P, Besler C, Schmitz T, Bekeredjian R, Nickenig G, Möllmann H et al. Short-term outcomes of tricuspid edge-to-edge repair in clinical practice. *J Am Coll Cardiol* 2023;**82**:281–91.
  52. Dreyfus J, Galloo X, Taramasso M, Heitzinger G, Benfari G, Kresoja KP et al. TRI-SCORE and benefit of intervention in patients with severe tricuspid regurgitation. *Eur Heart J* 2023;**45**:586–97.
  53. Maisano F, Hahn R, Sorajja P, Praz F, Lurz P. Transcatheter treatment of the tricuspid valve: current status and perspectives. *Eur Heart J* 2024;**45**:876–94.
  54. Praz F, Muraru D, Kreidel F, Lurz P, Hahn RT, Delgado V et al. Transcatheter treatment for tricuspid valve disease. *EuroIntervention* 2021;**17**:791–808.
  55. Nickenig G, Weber M, Schuler R, Hausleiter J, Nabauer M, von Bardeleben RS et al. Tricuspid valve repair with the Cardioband system: two-year outcomes of the multicenter, prospective TRI-REPAIR study. *EuroIntervention* 2021;**16**:e1264–71.
  56. Hahn RT, Makkar R, Thourani VH, Makar M, Sharma RP, Haeffele C et al. Transcatheter valve replacement in severe tricuspid regurgitation. *N Engl J Med* 2025;**392**:115–26.
  57. Chen M, Moschovitis A, Taramasso M. Pacemaker lead dislocation during TriValve procedure with an extremely small superior vena cava. *Int J Cardiovasc Imaging* 2024;**40**:1149–51.
  58. Mehr M, Taramasso M, Besler C, Ruf T, Connelly KA, Weber M et al. 1-Year outcomes after edge-to-edge valve repair for symptomatic tricuspid regurgitation: results from the TriValve registry. *JACC Cardiovasc Interv* 2019;**12**:1451–61.
  59. Blasco-Turrión S, Briedis K, Estévez-Loureiro R, Sánchez-Recalde A, Cruz-González I, Pascual I et al. Bicaval TriValve implantation in patients with severe symptomatic tricuspid regurgitation: 1-year follow-up outcomes. *JACC Cardiovasc Interv* 2024;**17**:60–72.
  60. Gabriels JK, Schaller RD, Koss E, Rutkin BJ, Carrillo RG, Epstein LM. Lead management in patients undergoing percutaneous tricuspid valve replacement or repair: a 'heart team' approach. *Europace* 2023;**25**:eua300.
  61. Slonim SM, Semba CP, Sze DY, Dake MD. Placement of SVC stents over pacemaker wires for the treatment of SVC syndrome. *J Vasc Interv Radiol* 2000;**11**:215–9.
  62. Saad TF, Myers GR, Ciccone J. Central vein stenosis or occlusion associated with cardiac rhythm management device leads in hemodialysis patients with ipsilateral arteriovenous access: a retrospective study of treatment using stents or stent-grafts. *J Vasc Access* 2010;**11**:293–302.
  63. Plant A, Stewart F, Hooks D. Implantable cardioverter-defibrillator lead failure and revision following transcatheter bicaval valve (TriValve(R)) implantation. *J Cardiovasc Electrophysiol* 2024;**35**:1050–4.
  64. Olsen T, Jørgensen OD, Nielsen JC, Thøgersen AM, Philbert BT, Johansen JB. Incidence of device-related infection in 97 750 patients: clinical data from the complete Danish device-cohort (1982–2018). *Eur Heart J* 2019;**40**:1862–9.
  65. Blomström-Lundqvist C, Traykov V, Erba PA, Burri H, Nielsen JC, Bongiorni MG et al. European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections-endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). *Europace* 2020;**22**:515–49.
  66. Wilkoff BL, Boriani G, Mittal S, Poole JE, Kennergren C, Corey GR et al. Impact of cardiac implantable electronic device infection: a clinical and economic analysis of the WRAP-IT trial. *Circ Arrhythm Electrophysiol* 2020;**13**:e008280.
  67. Blomström-Lundqvist C, Traykov V, Erba PA, Burri H, Nielsen JC, Bongiorni MG et al. European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections-endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). *Eur J Cardiothorac Surg* 2020;**57**:E1–E31.
  68. Sheldon SH, Joyce LD, Friedman PA. Transvenous extraction of right ventricular leads jailed by a bioprosthetic tricuspid valve. *J Innov Card Rhythm Manag* 2013;**4**:1209–12.
  69. Paz Rios LH, Alsaad AA, Guerrero M, Metz MD. Tricuspid valve-in-valve jailing right ventricular lead is not free of risk. *Catheter Cardiovasc Interv* 2020;**96**:E758–60.
  70. Chourdakis E, Koniaris I, Osman N, Kounis N, Hahalis G, Werner N. Late infective endocarditis after transcatheter mitral valve reconstruction (MitraClip): a case report and a review of the literature. *Angiology* 2023;**74**:205–15.
  71. Yokoyama H, Ochiai T, Saito S. Infective endocarditis after transcatheter edge-to-edge repair for severe mitral regurgitation: a case report and a systematic review. *Catheter Cardiovasc Interv* 2023;**102**:367–74.
  72. Gabriels JK, Schaller RD, Koss E, Rutkin BJ, Carrillo RG, Epstein LM. Lead management in patients undergoing percutaneous tricuspid valve replacement or repair: a 'heart team' approach. *Europace* 2023;**25**:eua300.
  73. Deharo JC, Bongiorni M, Rozkovec A, Bracke F, Defaye P, Fernandez-Lozano I et al. Pathways for training and accreditation for transvenous lead extraction: a European Heart Rhythm Association position paper. *Europace* 2012;**14**:124–34.
  74. Bongiorni MG, Blomström-Lundqvist C, Kennergren C, Dagres N, Pison L, Svendsen JH et al. Current practice in transvenous lead extraction: a European Heart Rhythm Association EP Network survey. *Europace* 2012;**14**:783–6.

75. Kusumoto FM, Schoenfeld MH, Wilkoff BL, Berul CI, Birgersdotter-Green UM, Carrillo R et al. 2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction. *Heart Rhythm* 2017;**14**:e503–51.
76. Bongioni MG, Burri H, Deharo JC, Starck C, Kennergren C, Saghy L et al. 2018 EHRA expert consensus statement on lead extraction: recommendations on definitions, endpoints, research trial design, and data collection requirements for clinical scientific studies and registries: endorsed by APHRS/HRS/LAHS. *Europace* 2018;**20**:1217.
77. Wilkoff BL, Love CJ, Byrd CL, Bongioni MG, Carrillo RG, Crossley GH et al. Transvenous lead extraction: Heart Rhythm Society expert consensus on facilities, training, indications, and patient management: this document was endorsed by the American Heart Association (AHA). *Heart Rhythm* 2009;**6**:1085–104.
78. Bongioni MG, Marinskis G, Lip GY, Svendsen JH, Dobreaanu D, Blomström-Lundqvist C et al. How European centres diagnose, treat, and prevent CIED infections: results of an European Heart Rhythm Association survey. *Europace* 2012;**14**:1666–9.
79. Bongioni MG, Kennergren C, Butter C, Deharo JC, Kutarski A, Rinaldi CA et al. The European lead extraction controlled (ELECTRa) study: a European heart rhythm association (EHRA) registry of transvenous lead extraction outcomes. *Eur Heart J* 2017;**38**:2995–3005.
80. Bongioni MG, Soldati E, Zucchelli G, Di Cori A, Segreti L, De Lucia R et al. Transvenous removal of pacing and implantable cardiac defibrillating leads using single sheath mechanical dilatation and multiple venous approaches: high success rate and safety in more than 2000 leads. *Eur Heart J* 2008;**29**:2886–93.
81. Wazni O, Epstein LM, Carrillo RG, Love C, Adler SV, Riggio DW et al. Lead extraction in the contemporary setting: the LExiCon study: an observational retrospective study of consecutive laser lead extractions. *J Am Coll Cardiol* 2010;**55**:579–86.
82. Byrd CL, Wilkoff BL, Love CJ, Sellers TD, Reiser C. Clinical study of the laser sheath for lead extraction: the total experience in the United States. *Pacing Clin Electrophysiol* 2002;**25**:804–8.
83. Neuzil P, Taborsky M, Rezek Z, Vopalka R, Sediva L, Niederle P et al. Pacemaker and ICD lead extraction with electrosurgical dissection sheaths and standard transvenous extraction systems: results of a randomized trial. *Europace* 2007;**9**:98–104.
84. Scott PA, Chow W, Ellis E, Morgan JM, Roberts PR. Extraction of pacemaker and implantable cardioverter defibrillator leads: a single-centre study of electrosurgical and laser extraction. *Europace* 2009;**11**:1501–4.
85. Mazzone P, Tsiachris D, Marzi A, Ciconte G, Paglino G, Sora N et al. Advanced techniques for chronic lead extraction: heading from the laser towards the evolution system. *Europace* 2013;**15**:1771–6.
86. Bongioni MG, Segreti L, Di Cori A, Zucchelli G, Viani S, Paperini L et al. Safety and efficacy of internal transjugular approach for transvenous extraction of implantable cardioverter defibrillator leads. *Europace* 2014;**16**:1356–62.
87. Koneru JN, Ellenbogen KA. High-risk lead extraction using a hybrid approach: the blade and the lightsaber. *J Cardiovasc Electrophysiol* 2014;**25**:622–3.
88. Fischer A, Love B, Hansalia R, Mehta D. Transfemoral snaring and stabilization of pacemaker and defibrillator leads to maintain vascular access during lead extraction. *Pacing Clin Electrophysiol* 2009;**32**:336–9.
89. Hamid S, Arujuna A, Ginks M, McPhail M, Patel N, Bucknall C et al. Pacemaker and defibrillator lead extraction: predictors of mortality during follow-up. *Pacing Clin Electrophysiol* 2010;**33**:209–16.
90. Brunner MP, Cronin EM, Wazni O, Baranowski B, Saliba WJ, Sabik JF et al. Outcomes of patients requiring emergent surgical or endovascular intervention for catastrophic complications during transvenous lead extraction. *Heart Rhythm* 2014;**11**:419–25.
91. Zucchelli G, Di Cori A, Segreti L, Larocche C, Blomstrom-Lundqvist C, Kutarski A et al. Major cardiac and vascular complications after transvenous lead extraction: acute outcome and predictive factors from the ESC-EHRA ELECTRa (European Lead Extraction ConTrolled) registry. *Europace* 2019;**21**:771–80.
92. Diemberger I, Mazzotti A, Biffi M, Massaro G, Martignani C, Ziacchi M et al. From lead management to implanted patient management: systematic review and meta-analysis of the last 15 years of experience in lead extraction. *Expert Rev Med Devices* 2013;**10**:551–73.
93. Akhtar Z, Kontogiannis C, Georgiopoulos G, Starck CT, Leung LWM, Lee SY et al. Comparison of non-laser and laser transvenous lead extraction: a systematic review and meta-analysis. *Europace* 2023;**25**:euaad316.
94. Rinaldi CA, Diemberger I, Biffi M, Gao YR, Sizto E, Jin N et al. Safety and success of transvenous lead extraction using excimer laser sheaths: a meta-analysis of over 1700 patients. *Europace* 2023;**25**:euaad298.
95. Cecchin F, Atallah J, Walsh EP, Triedman JK, Alexander ME, Berul CI. Lead extraction in pediatric and congenital heart disease patients. *Circ Arrhythm Electrophysiol* 2010;**3**:437–44.
96. Giannotti Santoro M, Segreti L, Zucchelli G, Barletta V, Fiorentini F, Di Cori A et al. Transvenous lead extraction: efficacy and safety of the procedure in octogenarian patients. *Pacing Clin Electrophysiol* 2020;**43**:382–7.
97. Diemberger I, Segreti L, Rinaldi CA, Svendsen JH, Kutarski A, Younis A et al. Transvenous lead extraction in patients with cardiac implantable device: the impact of systemic and local infection on clinical outcomes—an ESC-EHRA ELECTRa (European lead extraction controlled) registry substudy. *Biology (Basel)* 2022;**11**:615.
98. Polewczyk A, Rinaldi CA, Sohal M, Golzio P-G, Claridge S, Cano O et al. Transvenous lead extraction procedures in women based on ESC-EHRA EORP European Lead Extraction ConTrolled ELECTRa registry: is female sex a predictor of complications? *Europace* 2019;**21**:1890–9.
99. Segreti L, Bongioni MG, Barletta V, Parollo M, Di Cori A, Fiorentini F et al. Transvenous lead extraction: efficacy and safety of the procedure in female patients. *Heart Rhythm* 2023;**4**:625–31.
100. Di Cori A, Auricchio A, Regoli F, Blomström-Lundqvist C, Butter C, Dagres N et al. Clinical impact of antithrombotic therapy in transvenous lead extraction complications: a sub-analysis from the ESC-EORP EHRA ELECTRa (European Lead Extraction ConTrolled) registry. *Europace* 2019;**21**:1096–105.
101. Segreti L, Rinaldi CA, Claridge S, Svendsen JH, Blomstrom-Lundqvist C, Auricchio A et al. Procedural outcomes associated with transvenous lead extraction in patients with abandoned leads: an ESC-EHRA ELECTRa (European Lead Extraction ConTrolled) registry sub-analysis. *Europace* 2019;**21**:645–54.
102. Regoli F, Auricchio A, Di Cori A, Segreti L, Blomström-Lundqvist C, Butter C et al. Impact of anticoagulation therapy on outcomes in patients with cardiac implantable resynchronization devices undergoing transvenous lead extraction: a substudy of the ESC-EHRA EORP ELECTRa (European Lead Extraction ConTrolled) registry. *J Cardiovasc Electrophysiol* 2019;**30**:1086–95.
103. Segreti L, Di Cori A, Soldati E, Zucchelli G, Viani S, Paperini L et al. Major predictors of fibrous adhesions in transvenous implantable cardioverter-defibrillator lead extraction. *Heart Rhythm* 2014;**11**:2196–201.
104. Di Cori A, Bongioni MG, Zucchelli G, Segreti L, Viani S, De Lucia R et al. Large, single-center experience in transvenous coronary sinus lead extraction: procedural outcomes and predictors for mechanical dilatation. *Pacing Clin Electrophysiol* 2012;**35**:215–22.
105. Di Cori A, Bongioni MG, Zucchelli G, Lilli A, Coluccia G, Fabiani I et al. Short-term extraction profile of cardiac pacing leads with hybrid silicone-polyurethane insulator: a pilot study. *Int J Cardiol* 2013;**168**:4432–3.
106. Di Cori A, Bongioni MG, Zucchelli G, Segreti L, Viani S, Paperini L et al. Transvenous extraction performance of expanded polytetrafluoroethylene covered ICD leads in comparison to traditional ICD leads in humans. *Pacing Clin Electrophysiol* 2010;**33**:1376–81.
107. Bongioni MG, Di Cori A, Segreti L, Zucchelli G, Viani S, Paperini L et al. Transvenous extraction profile of Riata leads: procedural outcomes and technical complexity of mechanical removal. *Heart Rhythm* 2015;**12**:580–7.
108. Maytin M, Carrillo RG, Baltodano P, Schaefer RH, Bongioni MG, Di Cori A et al. Multicenter experience with transvenous lead extraction of active fixation coronary sinus leads. *Pacing Clin Electrophysiol* 2012;**35**:641–7.
109. Gabriels JK, Kim BS, Shoda M, Birgersdotter-Green U, Di Cori A, Zucchelli G et al. International experience with transvenous lead extractions of an active-fixation coronary sinus pacing lead. *Heart Rhythm* 2024;**21**:686–7.
110. Sidhu BS, Gould J, Bunce C, Elliott M, Mehta V, Kennergren C et al. The effect of centre volume and procedure location on major complications and mortality from transvenous lead extraction: an ESC EHRA EORP European Lead Extraction ConTrolled ELECTRa registry subanalysis. *Europace* 2020;**22**:1718–28.
111. Racine H-P, Jacques F, Philippon F. The effect of centre volume and procedure location on major complications and mortality from transvenous lead extraction: an ESC EHRA EORP European Lead Extraction ConTrolled ELECTRa registry subanalysis. *Europace* 2021;**23**:1149.
112. Agarwal SK, Kamireddy S, Nemec J, Voigt A, Saba S. Predictors of complications of endovascular chronic lead extractions from pacemakers and defibrillators: a single-operator experience. *J Cardiovasc Electrophysiol* 2009;**20**:171–5.
113. Fu HX, Huang XM, Zhong L, Osborn MJ, Asirvatham SJ, Espinosa RE et al. Outcomes and complications of lead removal: can we establish a risk stratification schema for a collaborative and effective approach? *Pacing Clin Electrophysiol* 2015;**38**:1439–47.
114. Bongioni MG, Segreti L, Di Cori A, Zucchelli G, Paperini L, Viani S et al. Overcoming the current issues surrounding device leads: reducing the complications during extraction. *Expert Rev Med Devices* 2017;**14**:469–80.
115. Bontempi L, Vassanelli F, Cerini M, D'Aloia A, Vizzardi E, Gargaro A et al. Predicting the difficulty of a lead extraction procedure: the LED index. *J Cardiovasc Med (Hagerstown)* 2014;**15**:668–73.
116. Kancharla K, Acker NG, Li Z, Samineni S, Cai C, Espinosa RE et al. Efficacy and safety of transvenous lead extraction in the device laboratory and operating room guided by a novel risk stratification scheme. *JACC Clin Electrophysiol* 2019;**5**:174–82.
117. Jacheč W, Polewczyk A, Polewczyk M, Tomasik A, Kutarski A. Transvenous lead extraction SAFETY score for risk stratification and proper patient selection for removal procedures using mechanical tools. *J Clin Med* 2020;**9**:361.
118. Sidhu BS, Ayis S, Gould J, Elliott MK, Mehta V, Kennergren C et al. Risk stratification of patients undergoing transvenous lead extraction with the ELECTRa Registry Outcome Score (EROS): an ESC EHRA EORP European lead extraction ConTrolled ELECTRa registry analysis. *Europace* 2021;**23**:1462–71.
119. Mehta VS, O'Brien H, Elliott MK, Wijesuriya N, Auricchio A, Ayis S et al. Machine learning-derived major adverse event prediction of patients undergoing transvenous

- lead extraction: using the ESC EHRA EORP European lead extraction ConTrolled ELECTRa registry. *Heart Rhythm* 2022;**19**:885–93.
120. Mehta VS, Ma Y, Wijesuriya N, Devere F, Howell S, Elliott MK *et al*. Enhancing transvenous lead extraction risk prediction: integrating imaging biomarkers into machine learning models. *Heart Rhythm* 2024;**21**:919–28.
  121. Lin AY, Lupercio F, Ho G, Pollema T, Pretorius V, Birgersdotter-Green U. Safety and efficacy of cardiovascular implantable electronic device extraction in elderly patients: a meta-analysis and systematic review. *Heart Rhythm* 2020;**17**:250–8.
  122. Roelfse S, Bracke F, Meijer A, Van Gelder B, Van Dantzig JM, Botman CJ *et al*. Transesophageal echocardiographic evaluation of tricuspid valve regurgitation during pacemaker and implantable cardioverter defibrillator lead extraction. *Pacing Clin Electrophysiol* 2002;**25**:1583–6.
  123. Franceschi F, Thuny F, Giorgi R, Sanaa I, Peyrouse E, Assouan X *et al*. Incidence, risk factors, and outcome of traumatic tricuspid regurgitation after percutaneous ventricular lead removal. *J Am Coll Cardiol* 2009;**53**:2168–74.
  124. Glover B, Watkins S, Mariani J, Yap S, Asta J, Cusimano R *et al*. Prevalence of tricuspid regurgitation and pericardial effusions following pacemaker and defibrillator lead extraction. *Int J Cardiol* 2010;**145**:593–4.
  125. Coffey JO, Sager SJ, Gangireddy S, Levine A, Viles-Gonzalez JF, Fischer A. The impact of transvenous lead extraction on tricuspid valve function. *Pacing Clin Electrophysiol* 2014;**37**:19–24.
  126. Givon A, Vedernikova N, Luria D, Vatury O, Kuperstein R, Feinberg MS *et al*. Tricuspid regurgitation following lead extraction: risk factors and clinical course. *Isr Med Assoc J* 2016;**18**:18–22.
  127. Rodriguez Y, Mesa J, Arguelles E, Carrillo RG. Tricuspid insufficiency after laser lead extraction. *Pacing Clin Electrophysiol* 2013;**36**:939–44.
  128. Migliore F, Pittorru R, De Lazzari M, Dall'Aglia PB, Cecchetto A, Previtero M *et al*. Evaluation of tricuspid valve regurgitation following transvenous rotational mechanical lead extraction. *Europace* 2024;**26**:euae191.
  129. Candinas R, Duru F, Schneider J, Lüscher TF, Stokes K. Postmortem analysis of encapsulation around long-term ventricular endocardial pacing leads. *Mayo Clin Proc* 1999;**74**:120–5.
  130. Polewczak A, Jacheć W, Nowosielecka D, Tomaszewski A, Brzozowski W, Szczęśniak-Stańczyk D *et al*. Lead dependent tricuspid valve dysfunction-risk factors, improvement after transvenous lead extraction and long-term prognosis. *J Clin Med* 2021;**11**:89.
  131. Nazmul MN, Cha YM, Lin G, Asirvatham SJ, Powell BD. Percutaneous pacemaker or implantable cardioverter-defibrillator lead removal in an attempt to improve symptomatic tricuspid regurgitation. *Europace* 2013;**15**:409–13.
  132. Patel D, Vatterott P, Piccini J, Epstein LM, Hakmi S, Syed I *et al*. Prospective evaluation of the correlation between gated cardiac computed tomography detected vascular fibrosis and ease of transvenous lead extraction. *Circ Arrhythm Electrophysiol* 2022;**15**:e010779.
  133. Tułęcki L, Polewczak A, Jacheć W, Nowosielecka D, Tomków K, Stefańczyk P *et al*. Analysis of risk factors for major complications of 1500 transvenous lead extraction procedures with especial attention to tricuspid valve damage. *Int J Environ Res Public Health* 2021;**18**:9100.
  134. Svennberg E, Jacobs K, McVeigh E, Pretorius V, Birgersdotter-Green U. Computed tomography-guided risk assessment in percutaneous lead extraction. *JACC Clin Electrophysiol* 2019;**5**:1439–46.
  135. Saad TF, Hentschel DM, Koplan B, Wasse H, Asif A, Patel DV *et al*. Cardiovascular implantable electronic device leads in CKD and ESRD patients: review and recommendations for practice. *Semin Dial* 2013;**26**:114–23.
  136. Schaller RD, Giri J, Epstein AE. Entrapped leads after transcatheter tricuspid valve replacement. *JACC Cardiovasc Interv* 2021;**14**:715–6.
  137. Noheria A, Van Zyl M, Scott LR, Srivathsan K, Madhavan M, Asirvatham SJ *et al*. Single-site ventricular pacing via the coronary sinus in patients with tricuspid valve disease. *Europace* 2018;**20**:636–42.
  138. Arps K, Li B, Allen JC Jr, Alenezi F, Frazier-Mills C, Al-Khatib SM *et al*. Association of leadless pacing with ventricular and valvular function. *J Cardiovasc Electrophysiol* 2023;**34**:2233–42.
  139. Garweg C, Duchenne J, Vandenberk B, Mao Y, Ector J, Haemers P *et al*. Evolution of ventricular and valve function in patients with right ventricular pacing—A randomized controlled trial comparing leadless and conventional pacing. *Pacing Clin Electrophysiol* 2023;**46**:1455–64.
  140. Fink T, Eitz T, Sciacca V, Rudolph V, Sohns C, Sommer P *et al*. Transfemoral leadless pacemaker implantation after interventional or surgical tricuspid valve repair. *Europace* 2024;**26**:euae111.
  141. Carabelli A, Jabeur M, Jacon P, Rinaldi CA, Leclercq C, Rovaris G *et al*. European experience with a first totally leadless cardiac resynchronization therapy pacemaker system. *Europace* 2021;**23**:740–7.
  142. Torres-Quintero L, Molina-Lerma M, Cabrera-Borrego E, García-Orta R, Tercedor-Sánchez L, Álvarez M. His-bundle pacing from the right atrium in a patient with tetralogy of Fallot and a prosthetic tricuspid valve. *JACC Clin Electrophysiol* 2020;**6**:745–6.
  143. Elliott MK, Vergara P, Wijesuriya N, Mehta VS, Bosco P, Jacon P *et al*. Feasibility of leadless left ventricular septal pacing with the WiSE-CRT system to target the left bundle branch area: a porcine model and multicenter patient experience. *Heart Rhythm* 2022;**19**:1974–83.
  144. Knops RE, Lloyd MS, Roberts PR, Wright DJ, Boersma LVA, Doshi R *et al*. A modular communicative leadless pacing-defibrillator system. *N Engl J Med* 2024;**391**:1402–12.
  145. Lancellotti P, Pibarot P, Chambers J, La Canna G, Pepi M, Dulgheru R *et al*. Multi-modality imaging assessment of native valvular regurgitation: an EACVI and ESC council of valvular heart disease position paper. *Eur Heart J Cardiovasc Imaging* 2022;**23**:e171–232.
  146. Mediratta A, Addetia K, Yamat M, Moss JD, Nayak HM, Burke MC *et al*. 3D echocardiographic location of implantable device leads and mechanism of associated tricuspid regurgitation. *JACC Cardiovasc Imaging* 2014;**7**:337–47.
  147. Nucifora G, Badano LP, Allocca G, Gianfagna P, Proclemer A, Cinello M *et al*. Severe tricuspid regurgitation due to entrapment of the anterior leaflet of the valve by a permanent pacemaker lead: role of real time three-dimensional echocardiography. *Echocardiography* 2007;**24**:649–52.
  148. Hell MM, Emrich T, Kreidel F, Kreitner KF, Schoepf UJ, Münzel T *et al*. Computed tomography imaging needs for novel transcatheter tricuspid valve repair and replacement therapies. *Eur Heart J Cardiovasc Imaging* 2021;**22**:601–10.
  149. Bartkowiak J, Vivekanantham H, Kassam M, Dernektsi C, Agarwal V, Lebehn M *et al*. Computed tomography anatomic predictors of outcomes in patients undergoing tricuspid transcatheter edge-to-edge repair. *J Cardiovasc Comput Tomogr* 2024;**18**:259–66.
  150. Korantzopoulos P, Letsas KP, Grekas G, Goudevenos JA. Pacemaker dependency after implantation of electrophysiological devices. *Europace* 2009;**11**:1151–5.
  151. Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA *et al*. 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. *Eur Heart J* 2022;**43**:3997–4126.
  152. Ferrick AM, Raj SR, Deneke T, Kojodjojo P, Lopez-Cabanillas N, Abe H *et al*. 2023 HRS/EHRA/APHR/LAHR expert consensus statement on practical management of the remote device clinic. *Europace* 2023;**25**:eua123.
  153. Delgado V, Ajmone Marsan N, de Waha S, Bonaros N, Brida M, Burri H *et al*. 2023 ESC guidelines for the management of endocarditis: developed by the task force on the management of endocarditis of the European Society of Cardiology (ESC) endorsed by the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Nuclear Medicine (EANM). *Eur Heart J* 2023;**44**:3948–4042.
  154. Tan EM, DeSimone DC, Sohail MR, Baddour LM, Wilson WR, Steckelberg JM *et al*. Outcomes in patients with cardiovascular implantable electronic device infection managed with chronic antibiotic suppression. *Clin Infect Dis* 2017;**64**:1516–21.
  155. Peacock JE Jr, Stafford JM, Le K, Sohail MR, Baddour LM, Prutkin JM *et al*. Attempted salvage of infected cardiovascular implantable electronic devices: are there clinical factors that predict success? *Pacing Clin Electrophysiol* 2018;**41**:524–31.
  156. Topaz M, Chorin E, Schwartz AL, Hochstadt A, Shotan A, Ashkenazi I *et al*. Regional antibiotic delivery for implanted cardiovascular electronic device infections. *J Am Coll Cardiol* 2023;**81**:119–33.